Ulf Jungnelius MD, CEO, Isofol Medical discusses the increasing incidence of colorectal cancer as a global issue and the current challenges in treating this devastating disease. Dr. Jungnelius also talks about the company's drug candidate, arfolitixorin, currently being studied in a global Phase 3 clinical trial with the aim to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer.
#colorectalcancer #CRC #ColonCancer #MetastaticColorectalCancer #chemotherapy #FirstLineTreatment
Isofolmedical.com
Download the transcript here
Empowered Patient Podcast